Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
37.36
+0.66 (1.80%)
At close: Aug 13, 2025, 4:00 PM
37.94
+0.58 (1.55%)
After-hours: Aug 13, 2025, 5:37 PM EDT
Apogee Therapeutics Employees
Apogee Therapeutics had 196 employees as of December 31, 2024. The number of employees increased by 105 or 115.38% compared to the previous year.
Employees
196
Change (1Y)
105
Growth (1Y)
115.38%
Revenue / Employee
n/a
Profits / Employee
-$1,212,607
Market Cap
2.18B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 196 | 105 | 115.38% |
| Dec 31, 2023 | 91 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
APGE News
- 2 days ago - Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis - Seeking Alpha
- 5 weeks ago - Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis - GlobeNewsWire
- 5 weeks ago - Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 - GlobeNewsWire
- 2 months ago - Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class - Seeking Alpha
- 3 months ago - Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma - GlobeNewsWire